Gilead Sciences, Inc (NASDAQ:GILD) does about 9.79M shares in volume on a normal day but saw 7928105 shares change hands in the recent trading day. The company now has a market cap of 135.70B USD. Its current market price is $109.09, marking an increase of 1.60% compared to the previous close of $107.37. The 52 week high reached by this stock is $119.96 whilst the lowest price level in 52 weeks is $62.07. The script in recent trading has seen the stock touch a high of $132 and a low of $83.
17 analysts observing the Gilead Sciences, Inc (GILD) stock have set the 12-month price targets for the company’s shares at between $83 and $132. The consensus objective for the share price is $116.05, suggesting that the stock has a potential upside of 6.0% over the period. The median price target is 13.42% away from the current levels at $126.
FactSet Research has provided data showing that 17 brokerages have issued ratings for the stock. 0 analysts have rated it as a sell, while 0 advise that it is a overweight. 11 analysts have rated it as a buy and 6 have advised that investors hold their positions. The consensus recommendation rating is Buy and Wall Street’s advice is for investors to Strong Buy the stock.
The company shares received a number of brokerage firm price updates over the past month, with the latest being on April 22, 2025 when Cantor Fitzgerald resumed the stock to “Overweight” and issued a price target of $125. Deutsche Bank upgraded its price target at $120.
The current price level is 5.66%, 3.26%, and 15.06% away from its SMA20, SMA50, and SMA200 respectively, with the GILD price moving above the 50-day SMA on current market day. Gilead Sciences, Inc (GILD) stock is up 2.76% over the week and 5.74% over the past month. Its price is 18.10% year-to-date and 60.90% over the past year.
The company’s next earnings report forecasts estimating quarterly EPS at 1.95 and 7.98 for whole year. Expected sales for next quarter are $7.39B, which analysts say will come at $28.66B for the current fiscal year and next year at $29.7B. In addition, estimates put the company’s current quarterly revenue at an average of $6.94B.
Its 12-month price target is $126. To reach the target analysts have set, the stock logically needs to grow 6.0 percent from here. Of course, the average price target is just what the average analysts believe a stock will be worth in the next 52 weeks, and is only one metric. There are analysts with lower targets than the average, including one bearish Wall Street research firm advocating investors to wait for the price to pull back to $83, given the recent momentum. And then, on the bullish side of things, one analyst is expecting the stock to peak at $132.
Outstanding shares total 1.25B with insiders holding 0.12% of the shares and institutional holders owning 89.63% of the company’s common stock. The company has a return on investment of 14.44% and return on equity of 32.51%. The price to earnings ratio (P/E ratio) amounts to 22.94 while the forward price to earnings ratio is 12.80. The beta has a value of 0.30. Price to book ratio is 7.09 and price to sales ratio is 4.73.
